Zejula
Payments companies reported to CMS as associated with Zejula. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zejula, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zejula
These are the largest totals companies reported as associated with Zejula. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Chan | San Francisco, CA | Gynecologic Oncology | $101,639.81 |
| Mark Shahin | Hershey, PA | Gynecologic Oncology | $66,887.12 |
| Ivor Benjamin | Phoenix, AZ | Gynecologic Oncology | $57,053.43 |
| Amina Ahmed | Chicago, IL | Gynecologic Oncology | $49,762.04 |
| Dana Chase | Los Angeles, CA | Gynecologic Oncology | $47,908.30 |
| Nadim Bou Zgheib | Huntington, WV | Gynecologic Oncology | $45,610.59 |
| Dan Veljovich | Seattle, WA | $45,219.97 | |
| Joshua Kesterson | Newport, PA | Gynecologic Oncology | $41,161.46 |
| Cecelia Boardman | Richmond, VA | Gynecologic Oncology | $40,216.37 |
| Robert Morris | Detroit, MI | Gynecologic Oncology | $39,236.42 |
Prescribed Zejula?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.